Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin
Introduction
Brain iron accumulation, beyond that seen in age-matched controls, is frequently observed in Parkinson's disease (PD) affected brains (reviewed in (Gerlach et al., 2006)). Histochemical comparisons of postmortem brain tissue have found increased levels of iron deposits in the substantia nigra (SN) of Parkinsonian brains (Dexter et al., 1987, Sofic et al., 1991) and specifically in neurons of the SN (Oakley et al., 2007). These pathologic findings are further supported by magnetic resonance imaging (Bartzokis et al., 1999, Gorell et al., 1995, Martin et al., 2008, Michaeli et al., 2007) and transcranial ultrasound (Becker et al., 1995, Mehnert et al., 2010, Walter et al., 2002) studies that observed iron deposits in the SN in living idiopathic PD patients.
It is debatable whether this accumulation of iron is a cause, co-factor, or consequence of the dopaminergic (DA) cell death in PD. Iron is a very potent oxidation–reduction agent that can create oxidative stress in cells and prior work suggests that neurons may be more sensitive to alterations in iron (LaVaute et al., 2001, Moos et al., 1998) than other cell types in the brain. Iron is also hypothesized to aggravate some key pathogenic processes related to PD including alpha-synuclein fibril formation (Olivares et al., 2009, Uversky et al., 2001) and mitochondrial dysfunction (Horowitz and Greenamyre, 2010, Lin et al., 2001). Finally, iron may simply be a remnant of neuronal cell death (He et al., 2003).
Animal models provide some potential insight. Genetic knockouts of some iron-related genes, when not lethal, produce altered brain iron levels (LaVaute et al., 2001, Moos and Morgan, 2004, Patel et al., 2002). Iron administration to unaltered animals has resulted in brain iron accumulation (Sengstock et al., 1993) or iron accumulation with a decrease in dopamine levels (Sziraki et al., 1998, Wesemann et al., 1994). Iron feeding studies in animals have also observed decreased dopamine levels with a large excess of dietary iron (Kaur et al., 2007) and with iron in combination with toxins (Levenson et al., 2004, Peng et al., 2007). These observations suggest that iron is either a cause or a co-factor, not a consequence, of dopaminergic cells damage, possibly due to the role iron plays in the synthesis of tyrosine hydroxylase (Snyder and Connor, 2009). Therefore, we hypothesize that small imbalances in ferrous or ferric brain iron contribute to one or more of the pathogenic processes contributing to neurodegeneration in PD and propose to investigate this hypothesis by evaluating the associations between PD and iron-related genes.
To date, epidemiologic studies investigating associations between occupational or dietary iron exposure and PD have been unpersuasive, and the few reports of iron-related genes and PD have been predominantly in small studies, investigating rare exonic SNPs, and inconclusive (reviewed in (Rhodes and Ritz, 2008)). Nevertheless, studies in experimental models of PD support a role for iron in the etiology or progression of PD (e.g. (Ben-Shachar and Youdim, 1991, Fredriksson et al., 2001, Kaur et al., 2003)). To facilitate the investigation of the iron-PD hypothesis, we pooled data from three independent case–control studies: one each from the United States (US), Australia (AU), and France (FR). All studies were designed for the investigation of genetic variation; the US and FR studies were also designed to investigate the influence of pesticide exposure on PD etiology and, therefore, include subjects with an increased likelihood of exposure to pesticides. In this report, we present the results from our two-phase study of promoter region, intronic, and exonic SNPs specifically selected to span each of 16 iron-related candidate genes and their associations with PD in a pooled sample of 1286 idiopathic PD cases and 1391 controls.
Section snippets
Methods
For our two-phase design we screened a larger number of genetic variants in an initial study, the US Study described below, followed by genotyping of selected variants in two additional studies based on findings from the initial study. All three studies (Supplemental Table 1) were pooled for the final analysis.
Phase 1, screening in US Study
From the 84 SNPs screened in the US Study (phase 1; Supplementary Table 2), 12 out of 31 regions (haplotype blocks) contained one or more SNPs with a sufficient screening p-value for consideration in the phase 1 haplotype analysis. These 12 regions were in 10 of the 15 genes evaluated in the US Study: FRRS1, SLC40A1, TF (2 regions), CP (2 regions), HFE, TFR2, IREB2, CYB561, FECH, and HAMP (no SNPs in LTF, TFRC, FTMT, SLC11A2, and HEPH met the screening criterion). In the haplotype analysis of
Discussion
Based on the well-documented accumulation of iron in the substantia nigra (SN) of Parkinson's disease (PD) brains we pursued a hypothesis generating effort investigating genetic variants of iron-related genes for association with PD. Our results are intriguing and suggest of a role for genetic variants in transferrin and transferrin receptor 2 in the etiology or pathology of PD. While these findings must be considered exploratory, we observed a 15–20% decrease in risk of PD for subjects with
Acknowledgments
We are exceptionally grateful to all study participants, whose generosity made this research possible. We thank Drs. Jerome Rotter and Kent Taylor (Cedars-Sinai Medical Center) for their generous support in genotyping the US Study. The US study was funded in part by NIEHS Grants R01-ES010544, U54-ES012078, P01-ES016732; the Michael J. Fox Foundation; The Parkinson Alliance; the American Parkinson Disease Association; and the Veterans Administration Healthcare System (SW PADRECC). The Australian
References (76)
- et al.
Mri evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects
Magn. Reson. Imaging
(1999) - et al.
Variants in Tf and Hfe explain approximately 40% of genetic variation in serum-transferrin levels
Am. J. Hum. Genet.
(2009) - et al.
The Cys282tyr polymorphism in the Hfe gene in Australian Parkinson's disease patients
Neurosci. Lett.
(2002) - et al.
Increased nigral iron content in postmortem Parkinsonian brain
Lancet
(1987) - et al.
Neonatal iron potentiates adult Mptp-induced neurodegenerative and functional deficits
Parkinsonism Relat. Disord.
(2001) - et al.
Dopaminergic cell death precedes iron elevation in Mptp-injected monkeys
Free Radic. Biol. Med.
(2003) - et al.
Occurrence of depression and anxiety prior to Parkinson's disease
Parkinsonism Relat. Disord.
(2010) - et al.
Genetic or pharmacological iron chelation prevents Mptp-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease
Neuron
(2003) - et al.
Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age
Neurobiol. Aging
(2007) - et al.
Polymorphisms in the transferrin 5′ flanking region associated with differences in total iron binding capacity: possible implications in iron homeostasis
Blood Cells Mol. Dis.
(2001)